PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-19.78%
Negative net income growth while TRAW stands at 15.61%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
2.78%
Less D&A growth vs. TRAW's 100.00%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
37.14%
SBC growth while TRAW is negative at -2.17%. John Neff would see competitor possibly controlling share issuance more tightly.
172.06%
Slight usage while TRAW is negative at -76.39%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
172.06%
Some yoy usage while TRAW is negative at -114.75%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
-10743.19%
Both negative yoy, with TRAW at -200.00%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-10.71%
Both yoy CFO lines are negative, with TRAW at -7.10%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.75%
We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.18%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.